吉非替尼治疗非小细胞肺癌的临床研究进展

肺癌是肿瘤死亡的最常见原因,其中85%为非小细胞肺癌,且大多数患者有晚期的表现,患者5年的生成率仅为1%~5%,近年研发成功的酪氨酸激酶抑制剂,开启了肿瘤小分子靶向治疗的新时代,尤其是由阿斯利康公司研制并推出的吉非替尼,为晚期NSCLC患者又提供了一种有效的治疗药物。本文对吉非替尼治疗非小细胞肺癌的临床研究进展进行综述,其中包括全球范围内吉非替尼单药二线、一线和维持治疗,以及联合化疗治疗非小细胞肺癌的临床研究进展。

Progress in Clinical Studies of the Gefitinib Uesd in the Treatment of Non-small cell lung cancer(NSCLC)

Lung cancer is the most common cause of death,85% of non-small cell lung cancer,and most patients with advanced performance,generating 5-year rate was 1% ~ 5%. In recent years,successfully developed tyrosine kinase inhibitors,opened a new era of smallmolecule targeted cancer therapy. Especially the Gefitinib which is developed and launched by Astra Zeneca,provides another effective treatment for patients with advanced NSCLC. This paper gived an overview of worldwide clinical studies of Gefitinib in the treatment of non-small cell lung cancer,which included the monotherapy of Gefitinib in first-line,second-line and maintenance treatment,also the combination chemotherapy in non-small cell lung cancer.